This article is more than 5 years old. Information may no longer be current.

SpineGuard obtains regulatory clearance to sell PediGuard in China

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SpineGuard recently announced it has received regulatory clearance to market and sell its Classic PediGuard line of products in China, according to a company press release.

The China spine market is the second largest market after the United States, estimated to be worth more than $1 billion by 2019, according to IData Research. The market is expanding due to an aging population, improvement treatment rates and growing affordability, the release stated.

“This  regulatory  clearance  is  the  result  of  a  diligent  collaborative  process  with

General Care International,” Pierre Jérôme, co-founder and CEO of SpineGuard, said in the press release. “It is a major milestone for Spine Guard and further validates the value of our Dynamic Surgical Guidance-based PediGuard device for making spine surgery safer.”

Reference: www.spineguard.com.